Apel­lis grabs $60M to pay for a loom­ing PhI­II show­down with Alex­ion's Soliris

Back­ing up da­ta from small but promis­ing stud­ies for their ri­val ther­a­py to Soliris, Louisville-based Apel­lis has round­ed up a $60 mil­lion round to pay …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.